The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.
– Chronic Hepatitis C- Cirrhosis
Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Eligibility & Criteria
Ages Eligible for Study: 18 Years – 65 Years, Genders Eligible for Study: Both Criteria Inclusion Criteria:Age at entry 18-65 years; non-responders to previous treatment (minimum of 3 months) with an a interferon plus ribavirin; liver biopsy demonstrating cirrhosis Exclusion Criteria:Any other cause for liver disease other than chronic hepatitis C; history or presence of complications of cirrhosis; alcohol or illicit drug abuse or treatment with methadone within the past 2 years; diseases or conditions that could interfere with participation in the study